AngioDynamics, Inc. (NASDAQ:ANGO) CFO Purchases $22,640.00 in Stock

AngioDynamics, Inc. (NASDAQ:ANGO) CFO Stephen A. Trowbridge acquired 1,000 shares of the firm’s stock in a transaction dated Wednesday, January 12th. The shares were purchased at an average price of $22.64 per share, for a total transaction of $22,640.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of NASDAQ:ANGO opened at $22.63 on Friday. AngioDynamics, Inc. has a 52 week low of $17.61 and a 52 week high of $32.00. The firm has a fifty day simple moving average of $26.92 and a two-hundred day simple moving average of $27.01. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.43 and a quick ratio of 1.54.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Wednesday, January 5th. The medical instruments supplier reported ($0.02) EPS for the quarter. AngioDynamics had a negative return on equity of 0.24% and a negative net margin of 12.64%. The business had revenue of $78.30 million during the quarter, compared to analysts’ expectations of $77.90 million. During the same period in the previous year, the business earned $0.01 earnings per share. The business’s quarterly revenue was up 7.6% on a year-over-year basis. On average, equities research analysts predict that AngioDynamics, Inc. will post -0.01 EPS for the current year.

ANGO has been the topic of several recent analyst reports. Zacks Investment Research downgraded shares of AngioDynamics from a “strong-buy” rating to a “hold” rating and set a $27.00 price objective on the stock. in a research report on Wednesday, December 1st. raised shares of AngioDynamics from a “hold” rating to a “buy” rating and raised their target price for the company from $28.00 to $37.00 in a research note on Friday, October 15th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $32.00.

Several large investors have recently modified their holdings of the business. Point72 Hong Kong Ltd grew its stake in shares of AngioDynamics by 38.8% in the 3rd quarter. Point72 Hong Kong Ltd now owns 1,728 shares of the medical instruments supplier’s stock worth $45,000 after buying an additional 483 shares in the last quarter. HighTower Advisors LLC grew its stake in shares of AngioDynamics by 2.7% in the 3rd quarter. HighTower Advisors LLC now owns 19,871 shares of the medical instruments supplier’s stock worth $516,000 after buying an additional 519 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of AngioDynamics by 0.9% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 82,340 shares of the medical instruments supplier’s stock worth $2,234,000 after buying an additional 707 shares in the last quarter. First Mercantile Trust Co. lifted its holdings in shares of AngioDynamics by 25.4% in the 3rd quarter. First Mercantile Trust Co. now owns 4,626 shares of the medical instruments supplier’s stock worth $120,000 after acquiring an additional 937 shares during the last quarter. Finally, Louisiana State Employees Retirement System lifted its holdings in shares of AngioDynamics by 7.6% in the 3rd quarter. Louisiana State Employees Retirement System now owns 18,500 shares of the medical instruments supplier’s stock worth $480,000 after acquiring an additional 1,300 shares during the last quarter. 93.45% of the stock is owned by institutional investors and hedge funds.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. It offers ablation systems, fluid management systems, vascular access, angiographic, drainage. thrombolytic, and venous products.

Further Reading: How can you know how many shares are floating?

Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.